Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 14;1(3):100041.
doi: 10.1016/j.jtocrr.2020.100041. eCollection 2020 Sep.

Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib

Carlos Henrique A Teixeira  1 , Evandro S de Mello  2   3 , Cheng Tzu Yen  1 , Rodrigo de Morais Hanriot  4 , Riad Naim Younes  5
Affiliations
Case Reports

Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib

Carlos Henrique A Teixeira et al. JTO Clin Res Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Computed tomography with a 7.5 cm × 5 cm mass in the right lower lobe (July 13, 2018).
Figure 2
Figure 2
Computed tomography with a partial response after 12 months (August 8, 2019).
Figure 3
Figure 3
Pathologic findings. (A) Gross specimen revealing extensive tumor cystification (dotted line) with a focal nodular area (arrow) corresponding to the small cell carcinoma transformation; (B) Hematoxylin and eosin (×400) stained section with acinar adenocarcinoma (upper right half of the field) continuous to the focus of transformation for small cell carcinoma (lower left half); (C) Immunohistochemistry disclosing synaptophysin positivity in the small cell carcinoma component; (D) Ki-67 positivity in more than 90% of neuroendocrine neoplastic cells.
See this image and copyright information in PMC

References

    1. Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Paper presented at: ESMO 2018 Congress. October 19, 2018; Munich, Germany.
    1. Ramalingam S.S., Vansteenkiste J., Planchard D. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. - PubMed
    1. Leonetti A., Sharma S., Minari R., Perego P., Giovannetti E., Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–737. - PMC - PubMed
    1. Gomez D.R., Tang C., Zhang J. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–1565. - PMC - PubMed
    1. Xu Q., Zhou F., Liu H. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13:1383–1392. - PubMed

Publication types